TLR4 downregulation protects against cisplatin-induced ototoxicity in adult and pediatric patients with cancer.
Saved in:
| Title: | TLR4 downregulation protects against cisplatin-induced ototoxicity in adult and pediatric patients with cancer. |
|---|---|
| Authors: | Lee JJW; Department of Otolaryngology-Head and Neck Surgery, Sinai Health System, Toronto, Ontario, Canada., Latif A; Department of Medical Microbiology and Immunology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada., Scott EN; British Columbia Children's Hospital Research Institute, Vancouver, British Columbia, Canada; Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Thakral A; Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada., Mahler MB; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Brooks B; Audiology and Speech Pathology Department, BC Children's Hospital, Vancouver, British Columbia, Canada., Hueniken K; Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada., Billfalk-Kelly A; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada., Espin-Garcia O; Department of Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada., Zhan LJ; Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada., Rassekh SR; British Columbia Children's Hospital Research Institute, Vancouver, British Columbia, Canada; Department of Pediatrics, Division of Pediatric Hematology/Oncology/BMT, University of British Columbia, Vancouver, British Columbia, Canada., Pecheux L; Division of Pediatric Oncology, Department of Pediatrics, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada., Spavor M; Division of Pediatric Oncology, Department of Pediatrics, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada., Li Y; British Columbia Children's Hospital Research Institute, Vancouver, British Columbia, Canada., Goldstein D; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Department of Otolaryngology - Head and Neck Surgery, University Health Network, University of Toronto, Toronto, Ontario, Canada., Hope A; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada., Ross CJ; British Columbia Children's Hospital Research Institute, Vancouver, British Columbia, Canada; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada., Liu G; Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada; Division of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. Electronic address: geoffry.liu@uhn.ca., Carleton BC; British Columbia Children's Hospital Research Institute, Vancouver, British Columbia, Canada; Division of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Pharmaceutical Outcomes Programme, British Columbia Children's Hospital, Vancouver, British Columbia, Canada. Electronic address: bcarleton@popi.ubc.ca., Bhavsar AP; Department of Medical Microbiology and Immunology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada; Department of Pharmacology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada. Electronic address: amit.bhavsar@ualberta.ca. |
| Source: | The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2025 Feb; Vol. 392 (2), pp. 100057. Date of Electronic Publication: 2024 Dec 09. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0376362 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0103 (Electronic) Linking ISSN: 00223565 NLM ISO Abbreviation: J Pharmacol Exp Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
